These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
475 related articles for article (PubMed ID: 14517845)
1. Expression of AP-2alpha, c-kit, and cleaved caspase-6 and -3 in naevi and malignant melanomas of the skin. A possible role for caspases in melanoma progression? Woenckhaus C; Giebel J; Failing K; Fenic I; Dittberner T; Poetsch M J Pathol; 2003 Oct; 201(2):278-87. PubMed ID: 14517845 [TBL] [Abstract][Full Text] [Related]
2. Failure in post-transcriptional processing is a possible inactivation mechanism of AP-2alpha in cutaneous melanoma. Karjalainen JM; Kellokoski JK; Mannermaa AJ; Kujala HE; Moisio KI; Mitchell PJ; Eskelinen MJ; Alhava EM; Kosma VM Br J Cancer; 2000 Jun; 82(12):2015-21. PubMed ID: 10864211 [TBL] [Abstract][Full Text] [Related]
4. TTC4, a novel candidate tumor suppressor gene at 1p31 is often mutated in malignant melanoma of the skin. Poetsch M; Dittberner T; Cowell JK; Woenckhaus C Oncogene; 2000 Nov; 19(50):5817-20. PubMed ID: 11126369 [TBL] [Abstract][Full Text] [Related]
5. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Montone KT; van Belle P; Elenitsas R; Elder DE Mod Pathol; 1997 Sep; 10(9):939-44. PubMed ID: 9310959 [TBL] [Abstract][Full Text] [Related]
6. Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas. Heimberger AB; McGary EC; Suki D; Ruiz M; Wang H; Fuller GN; Bar-Eli M Clin Cancer Res; 2005 Jan; 11(1):267-72. PubMed ID: 15671555 [TBL] [Abstract][Full Text] [Related]
7. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Willmore-Payne C; Holden JA; Tripp S; Layfield LJ Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115 [TBL] [Abstract][Full Text] [Related]
8. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions. Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148 [TBL] [Abstract][Full Text] [Related]
9. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation. Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347 [TBL] [Abstract][Full Text] [Related]
10. Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations. Demunter A; Libbrecht L; Degreef H; De Wolf-Peeters C; van den Oord JJ Mod Pathol; 2002 Apr; 15(4):454-61. PubMed ID: 11950921 [TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer. Gee JM; Robertson JF; Ellis IO; Nicholson RI; Hurst HC J Pathol; 1999 Dec; 189(4):514-20. PubMed ID: 10629551 [TBL] [Abstract][Full Text] [Related]
12. Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Huang S; Luca M; Gutman M; McConkey DJ; Langley KE; Lyman SD; Bar-Eli M Oncogene; 1996 Dec; 13(11):2339-47. PubMed ID: 8957075 [TBL] [Abstract][Full Text] [Related]
13. Differential expression of cerbB3 in naevi and malignant melanomas. Korabiowska M; Mirecka J; Brinck U; Hoefer K; Marx D; Schauer A Anticancer Res; 1996; 16(1):471-4. PubMed ID: 8615656 [TBL] [Abstract][Full Text] [Related]
15. Frameshift mutations of RIZ, but no point mutations in RIZ1 exons in malignant melanomas with deletions in 1p36. Poetsch M; Dittberner T; Woenckhaus C Oncogene; 2002 May; 21(19):3038-42. PubMed ID: 12082534 [TBL] [Abstract][Full Text] [Related]
16. Expression of neurotrophins and their receptors in pigment cell lesions of the skin. Innominato PF; Libbrecht L; van den Oord JJ J Pathol; 2001 May; 194(1):95-100. PubMed ID: 11329147 [TBL] [Abstract][Full Text] [Related]
17. Somatic activation of KIT in distinct subtypes of melanoma. Curtin JA; Busam K; Pinkel D; Bastian BC J Clin Oncol; 2006 Sep; 24(26):4340-6. PubMed ID: 16908931 [TBL] [Abstract][Full Text] [Related]
18. c-KIT is frequently mutated in bilateral germ cell tumours and down-regulated during progression from intratubular germ cell neoplasia to seminoma. Biermann K; Göke F; Nettersheim D; Eckert D; Zhou H; Kahl P; Gashaw I; Schorle H; Büttner R J Pathol; 2007 Nov; 213(3):311-8. PubMed ID: 17768701 [TBL] [Abstract][Full Text] [Related]
19. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Albino AP; Nanus DM; Mentle IR; Cordon-Cardo C; McNutt NS; Bressler J; Andreeff M Oncogene; 1989 Nov; 4(11):1363-74. PubMed ID: 2682463 [TBL] [Abstract][Full Text] [Related]
20. Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression. Gorski DH; Leal AD; Goydos JS J Am Coll Surg; 2003 Sep; 197(3):408-18. PubMed ID: 12946796 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]